Ying Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Lin Feng
Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, China
4 shared publications - Bo Liu
Department of Orthopaedics, Chongqing High-Tech Zone People’s Hospital, Chongqing, China
1 shared publication Hui-Fan Ji
Financial support and sponsorship: Nil
1 shared publicationJinhui Xu
Department of Dermatology Chongqing Hospital of Traditional Chinese Medicine Chongqing China
1 shared publicationLi-Li Lou
Financial support and sponsorship: Nil
1 shared publication- Lin Wang
Department of Dermatology, West China Hospital, Sichuan University
1 shared publication
Latest Publications
- 6 September 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 511
Cutaneous Metastasis From Lung Adenocarcinoma
- 6 September 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 511
Cutaneous Metastasis From Lung Adenocarcinoma
- Open Access
- 1 January 2023
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2023 (1)
Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate‐to‐Severe Atopic Dermatitis: An Updated Meta‐Analysis
Background. Blocking agent for immune cytokine pathways is a novel treatment for atopic dermatitis (AD). Janus kinase (JAK) family is one of the cytoplasmic tyrosine kinases that mediate a variety of cytokines. Eight randomized controlled trials (RCTs) of JAK1 inhibitors (upadacitinib and abrocitinib) in AD have been published in the past three years. Objective. To evaluate the efficacy and safety of JAK1 inhibitors and compare upadacitinib with abrocitinib for the treatment of moderate‐to‐severe AD. Methods. Two independent reviewers searched Medline, Embase, Web of Science, and Cochrane databases updated on Apr 11th, 2023. We included data from phase two and three RCTs. Primary outcomes included the proportion of Investigator’s Global Assessment (IGA) responders and Eczema Area and Severity Index‐75 (EASI‐75) responders. Results. In all, eight RCTs were included in our study with 4634 moderate‐to‐severe AD patients. Both JAK1 inhibitors showed apparent therapeutic effects, but the 200 mg abrocitinib group demonstrated less efficacy than the 30 mg upadacitinib group in IGA responders (end of treatment) and EASI‐75 responders (after 2 weeks of treatment). However, both JAK1 inhibitor groups demonstrated significantly higher risks of acne (9.0%) and headache (6.3%). Besides, upadacitinib showed significantly higher risks of upper respiratory tract infection (7.6%) and nasopharyngitis (9.7%), and abrocitinib showed significantly higher risks of nausea (9.6%). Conclusion. JAK1 inhibitors demonstrate promising efficacy in AD with rapid response and dose‐dependent response and significantly higher risks of acne and headache. Based on existing data, oral 30 mg upadacitinib QD has better outcome than oral 200 mg abrocitinib QD and is a recommended dosage regimen for moderate‐to‐severe AD patients. Oral 15 mg upadacitinib QD might be an alternative dosage regimen in case of treatment‐emergent adverse events.
- 1 January 2023
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2023 (1)
Open AccessUpadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate‐to‐Severe Atopic Dermatitis: An Updated Meta‐Analysis
Background. Blocking agent for immune cytokine pathways is a novel treatment for atopic dermatitis (AD). Janus kinase (JAK) family is one of the cytoplasmic tyrosine kinases that mediate a variety of cytokines. Eight randomized controlled trials (RCTs) of JAK1 inhibitors (upadacitinib and abrocitinib) in AD have been published in the past three years. Objective. To evaluate the efficacy and safety of JAK1 inhibitors and compare upadacitinib with abrocitinib for the treatment of moderate‐to‐severe AD. Methods. Two independent reviewers searched Medline, Embase, Web of Science, and Cochrane databases updated on Apr 11th, 2023. We included data from phase two and three RCTs. Primary outcomes included the proportion of Investigator’s Global Assessment (IGA) responders and Eczema Area and Severity Index‐75 (EASI‐75) responders. Results. In all, eight RCTs were included in our study with 4634 moderate‐to‐severe AD patients. Both JAK1 inhibitors showed apparent therapeutic effects, but the 200 mg abrocitinib group demonstrated less efficacy than the 30 mg upadacitinib group in IGA responders (end of treatment) and EASI‐75 responders (after 2 weeks of treatment). However, both JAK1 inhibitor groups demonstrated significantly higher risks of acne (9.0%) and headache (6.3%). Besides, upadacitinib showed significantly higher risks of upper respiratory tract infection (7.6%) and nasopharyngitis (9.7%), and abrocitinib showed significantly higher risks of nausea (9.6%). Conclusion. JAK1 inhibitors demonstrate promising efficacy in AD with rapid response and dose‐dependent response and significantly higher risks of acne and headache. Based on existing data, oral 30 mg upadacitinib QD has better outcome than oral 200 mg abrocitinib QD and is a recommended dosage regimen for moderate‐to‐severe AD patients. Oral 15 mg upadacitinib QD might be an alternative dosage regimen in case of treatment‐emergent adverse events.
- 22 April 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (9) , E695-E697
Leprosy: A life‐changing disease
- 22 April 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (9) , E695-E697
Leprosy: A life‐changing disease
- 8 December 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (4) , 441
Prurigo Pigmentosa
- 8 December 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (4) , 441
Prurigo Pigmentosa
- 8 December 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (5) , 541
Primary Systemic Amyloidosis
- 8 December 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (5) , 541
Primary Systemic Amyloidosis
- 30 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (3) , E103-E105
Adult xanthogranuloma on penis: a case report
- 30 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (3) , E103-E105
Adult xanthogranuloma on penis: a case report
- Open Access
- 1 March 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (10) , e19450
Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome
Rationale: Myelodysplastic syndrome (MDS) can be complicated with Crohn disease (CD). Irritable bowel disease (IBD) associated with MDS has already been reported in the past; however, hematopoietic stem cell transplantation (HSCT) is rarely performed. Herein, we report a case of CD with MDS for HSCT. Patient concerns: A 41-year-old man was hospitalized due to abdominal pain and intermittent fever for 40 days. Two years later, he was readmitted due to abdominal pain and diarrhea with fever for 10 days. Diagnosis: Symptoms, laboratory examinations, and imaging findings of the patient were indicative of CD complicated with MDS. Interventions: An allogeneic HSCT was performed. Outcomes: He died of severe lung infection 125 days post-transplantation. Lessons: The number of cases of CD combined with MDS remains insufficient, and no consensus opinions are available to date. Hence, HSCT is a very potential treatment method. Additional experiences are needed to determine its effectiveness.
- 1 March 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (10) , e19450
Open AccessAllogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome
Rationale: Myelodysplastic syndrome (MDS) can be complicated with Crohn disease (CD). Irritable bowel disease (IBD) associated with MDS has already been reported in the past; however, hematopoietic stem cell transplantation (HSCT) is rarely performed. Herein, we report a case of CD with MDS for HSCT. Patient concerns: A 41-year-old man was hospitalized due to abdominal pain and intermittent fever for 40 days. Two years later, he was readmitted due to abdominal pain and diarrhea with fever for 10 days. Diagnosis: Symptoms, laboratory examinations, and imaging findings of the patient were indicative of CD complicated with MDS. Interventions: An allogeneic HSCT was performed. Outcomes: He died of severe lung infection 125 days post-transplantation. Lessons: The number of cases of CD combined with MDS remains insufficient, and no consensus opinions are available to date. Hence, HSCT is a very potential treatment method. Additional experiences are needed to determine its effectiveness.